INTRODUCTION
Lung cancer is the most common cause of cancer-related death in the USA and worldwide accounting for more cancer-related deaths compared to colon, breast and prostate around 16% [3] . This is despite the fact that early-detected lung cancer is curable in patients with good performance status. However, the lack of early detection and accurate localization of lesion for tissue acquisition remains one of the biggest challenges in lung cancer management. Indeed, a recently published multicenter early detection screening trial performed using low-dose computerized tomography (CT) has shown the benefit of early detection in a selected high-risk cohort of patients [4] . Screening with low-dose CT results in a relative reduction of 20% mortality; however, 96.4% of nodules detected are false positive and 90.4% of those required further diagnostic investigations [4] . Choosing the most appropriate biopsy technique for suspected peripheral nodule can be a challenging clinical risk-benefit decision and factors such as tumor size, location, patient co-morbidities including emphysematous changes around the lesion, respiratory function and the pre-test probability of malignancy must be taken into account [5] [6] [7] .
Newer technologies, such as radial probe endobronchial ultrasound (Rp-EBUS), have the advantage of locating the peripheral suspicious lung lesion for cancer; however, they require the operator to have experience, special training, and memory of the three-dimensional tracheobronchial tree.
Rp-EBUS does not provide guidance to the bronchoscopist for choosing the correct airway to get to the target lesions; therefore, the overall diagnostic yield is low and operator dependent without the assistance of navigation. Recent 
VIRTUAL BRONCHOSCOPY AND VIRTUAL BRONCHOSCOPY NAVIGATION
While computerized-assisted transthoracic needle aspiration is one of the most frequently performed procedures, with the diagnostic yield approaching 65-90%, it is limited due to its complications, in particular pneumothorax, requiring chest tube placement and hospitalization in almost half of the patients in some studies [8] [9] [10] (Table 1) . Another method, video-assisted thoracic surgery (VATS), is considered a more invasive procedure for the diagnosis of peripheral pulmonary lesion and has its own constraints in terms of cost, duration of the procedure, localization of small nodules during the procedure, single lung ventilation and requirement of general anesthesia [11] . It is not a practical approach for all patients with lung nodules suspicious for cancer.
Although routine flexible bronchoscopy has been a conventional method to evaluate peripheral lung nodule, it is of limited diagnostic value [12] with the diagnostic yield ranging from 20% to 84% [13] [14] [15] . Success is further compromised if the lesion is smaller than 2 cm [15] , due to the inability to go beyond the subsegmental level and to steer endobronchial accessories directly into the lesion.
Therefore to investigate and establish the diagnosis of suspicious lung lesions, particularly located beyond the subsegmental level in the lung, there is a need for a safer and more accurate procedure, not only for early diagnosis of the lesion with less complications, but also to avoid unnecessary delay and surgical procedures. Virtual bronchoscopy is one such CT image-based technique that helps bronchoscopists to get to the lesion. It also forms the basis of novel navigation bronchoscopy technology.
Virtual bronchoscopy (VB) is a computer-guided bronchoscopy simulation facilitated by pre-procedural CT imaging. It provides the same view, angles and zoom settings as real-time bronchoscopy. It is the name given to the indirect and augmented reality visualization of the tracheobronchial tree from the spatial information derived from CT images. A key factor that determines airway Airway segmentation is the process of: 1. automated identification of the airways on each CT slice, with their walls outlined using ''threshold'' values, so that the computer can recognize the outlined region as airway;
2. the extraction of the identified and the structures outlined from the rest of the image using labels; 3. stacking together of these labeled images as a 3D airway tree.
Specific CT construction image parameters that provide good quality 3D volume, and subsequently detailed airway segmentation and virtual bronchoscopy, are under investigation and development [16] . However, a CT that is appropriately collimated to thin slices (0.5-1 mm) and overlaps the image reconstruction is generally used to prepare the VB images down to the peripheral bronchi [16, 17] .
There are two VB systems commercially available: the BF-NAVI system (Cybernet System Inc., Tokyo, Japan) and the LungPoint Ò system (Broncus Medical, Mountain View, CA, USA) (Fig. 1) . The BF-NAVI has been more extensively studied in humans, whereas LungPoint has limited data in pre-human studies [18, 19] . The efficacy of VB is variable in the diagnosis of peripheral lung lesions. It has been reported in the range of 44.4-78.9% [20] . When combined with fluoroscopy, VB has not shown improvement in diagnostic yield with an experienced bronchoscopist [21] . However, when used with radial probe EBUS for peripheral lesions exhibiting involved bronchi on CT, VB has been shown to improve the diagnostic yield to 94.4% vs. 77.8% [22, 23] . • electromagnetic emitter and tracking board,
• sensor (locatable guide wire),
• EWC (extended working channel), • CT lung model, and Coupling of this system to the virtual bronchoscopic images guides movement of the probe to the target lesion. The placement of our probe in a flexible catheter allows passage of standard bronchoscopic instruments and biopsy. MO, USA). The major differences between the two are the electromagnetic emitter board and the sensor device. The electromagnetic emitter board used in the i-Logic system is placed underneath the patient, whereas in SPiNDrive the field is projected from above the patients. The Sensor device in the i-Logic system (LG) is as described above: that is, a probe that can be passed through the working channel of the bronchoscope with a catheter guided sheath which comes in various angles (45, needles. E-TTNA has the potential to be performed when ENB is non-diagnostic in the same setting using the same CT scan that was performed for ENB procedure planning and performance.
However, at present, there are no clinical trials available comparing outcomes to standard CT-guided lung biopsy.
In addition to the above commercially available electromagnetic navigation systems, our group has developed a 3D electromagnetic navigation platform with airway segmentation and virtual bronchoscopy using an open source 3D slicer environment [25] (Figs. 2, 3) . The open source visualization software (3D Slicer http:// www.slicer.org) was further developed to create a detailed airway segmentation and virtual bronchoscopy model from acquired CT images in the DICOM format [16] .
Our navigational platform has been tested in vitro using the breathing lung model and 
Factors Influencing Yield
Despite the improved safety profile, the diagnostic yield of ENB remains less than that of TTNA. There are various patient, operator and technological factors that impact the diagnostic yield.
Patient and Operator Factors
Firstly, related to lesion, the size and location of the lesion influences the effectiveness of ENB.
The ENB platform is used for peripheral lung lesions, although, theoretically, it can be used to diagnose any suspicious lesion, located anywhere in the chest. However, it had been shown [42] that an airway going right into the lesion on the CT scan (bronchus sign) makes the lesion accessible to ENB and improves the diagnostic yield (Fig. 4) . If there is no bronchus sign, it is still possible to get to the lesion, but the diagnostic yield may not be as good as it would be if there was a bronchus sign. The diagnosis was 79% (30/38) in patients with a bronchus sign on CT imaging, but only in 4/13 (31%) with no discernible bronchus sign [42] . Moreover, the diagnostic yield is higher (88%) for a lesion located in the right middle lobe compared to that in the upper or lower lobes [43] . This may be due to the acute angle of the corresponding bronchus in the upper lobes and respiratory movement in the lower lobes [44] . The size of the lesion is also an independent factor that determines the diagnostic yield of the ENB [45] . In a prospective study of 180 consecutive ENB cases, the average lesion diameter was 29.6 vs. 17.6 mm in the diagnostic and non-diagnostic groups, respectively (p = 0.001) [46] . Surprisingly, the diagnostic yield for peripheral lesions reported in literature, both for the VB and ENB, is not significantly different [20-22, dose and slice thickness) for detailed 3D segmentation [16] , and the improvement of software to make it user friendly and cost-effective to help clinicians incorporate this technology in their practice. were not used during the study. Moreover, there was significantly less bleeding and the pneumothorax rate was 8% in the combined ENB/Rp-EBUS procedure [8, 57] . Another trial combining the VB and Rp-EBUS in patients with a positive bronchus sign (Fig. 4) showed that the diagnostic yield in the VB and non-VB groups was 94.4% vs. 77.8% (p = 0.004), respectively, particularly high for lesions smaller than 20 mm (94.6% vs. 70.7%; p = 0.006) [22] . A more recent trial suggested that the use of ENB after bronchoscopy, with a combination of Rp-EBUS and VB, led to a small increased yield with an overall yield of 70%
COMPLEMENTARY TECHNOLOGIES
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[29]. As before, probe position and lesion size influenced diagnostic yield; the authors suggest using all available modes of sampling when the lesion is reached. In interpreting trials, the expertise of the individual bronchoscopist must be considered and multicenter standardized comparisons would be extremely helpful in clarifying the best diagnostic pathway for peripheral lung nodules.
Additionally, multimodality guidance for 
ULTRATHIN BRONCHOSCOPY
Ultrathin bronchoscopy (UTB) allows reaching the bronchial tree beyond the conventional bronchoscope. It has an outer diameter of around 3 mm and the inner working channel diameter of just over 1 mm (1.2 mm). This allows deeper access into the endobronchial tree. However, given the thin and malleable nature of the scope with small working channel, it may pose difficulty in maneuvering through distal airways. A recent comparative trial for peripheral pulmonary lesion in 310 patients, combining either UTB or thin bronchoscopy (TB) that has external diameter of 4 mm with EBUS, fluoroscopy and VB has shown higher diagnostic histologic specimens in UTB vs. TB (74% vs. 59%; p = 0.044) [58] .
BRONCHOSCOPIC TRANSPARENCHYMAL NODULE ACCESS
One of the limitations of ENB is the challenge of accessing the nodules, which are eccentrically positioned and may not have the airway directly leading to them. To overcome this, a novel navigational approach, bronchoscopic transparenchymal nodule access (BTPNA) has been recently developed [59] [60] [61] . In this technique, the nodules are accessed through a transparenchymal ''off-road'' approach that is not dependent on the need to have an airway leading into the lesion. A computer software-generated tunneled path is created from the bronchial segments through the lung parenchyma directly to the peripheral lung lesions (Fig. 5) . A pilot study in a human population has demonstrated the safety and feasibility with adequate sampling and a yield of 83% (10/12 lesions) [59] . The mean transparenchymal tunnel size was 47 mm (10-90 mm), and an average of 3.3 samples was obtained in 12 patients. In this study, Archimedes Virtual Bronchoscopy Navigation System (Broncus Medical, Mountain View, CA, USA) was used in combination with computer-enhanced fused fluoroscopy. The mean fluoroscopy time was 5.5 (range 1.8-11.6) min. There was no pneumothorax or significant complications apart from transient troponin leak. However, in 2 out of 12 patients, the track could not be created [59] . BTPNA relies on the operator experience and the software to ensure that no major vessels are injured while tunneling through the lung parenchyma.
Further data to compare BTPNA against the current standard of transthoracic biopsy is warranted.
BRONCHOSCOPIC-GUIDED THERAPY FOR EARLY-STAGE PERIPHERAL LUNG CANCER
At present, bronchoscopic-guided therapy for lung cancer is limited to debulking of malignant airway obstruction with a number of different techniques including electrocautery [62] and treatment of early in situ cancer for the airways [62] . However, given the access to cancer through novel bronchoscopic techniques, there is a growing interest in bronchoscopic-guided therapy for early lung cancer, such as brachytherapy microwave ablation and radiofrequency ablation.
At present to our knowledge, only one group has presented their experience in a small case series. Delivery of cancer-directed therapy (brachytherapy) by ENB guidance has been demonstrated in the major airways [63, 64] .
However, the performance of this technique in comparison to standard therapy is not clear and continues to remain a potential research area.
COST ANALYSIS
There have been limited cost analysis studies of these techniques. It is widely accepted that CT-TTNA is cost-effective in comparison to VATS biopsy, especially with the availability of positron emission tomography-CT [65] .
Another study applied a decision tree analysis to compare downstream costs of Rp-EBUS with CT-TTNA [66] . The costs of Rp-EBUS and CT-TTNA appeared to be equivalent (US$2724 vs. US$2748), and the authors suggested that specific clinical-radiologic factors such as a positive bronchus sign and location of the lesion influence cost-benefit outcomes.
Further evaluation of patient preferences and their influence on cost-effectiveness were recommended. Finally, another study using 100 hypothetical patients created a decision tree with values from the literature to evaluate the clinical consequences and societal costs of a CT-TTNA versus ENB biopsy diagnosis of an SPN [67] . The authors concluded that an ENB with biopsy strategy is associated with decreased pneumothorax rate, but increased costs (by 3719US$ per case) and increased use of VATS (by 20%). Combining CT-guided biopsy and ENB with biopsy serially can decrease costs and complications. This, however, is clearly a significant cost increase and needs to be investigated further (Table 1) . Ideally, a strategy combining EBUS-TBNA of mediastinal lymph nodes followed by sequential guided biopsy techniques should be compared to separate mediastinal sampling plus CT-TTNA.
Improvements in dedicated EBUS scope such as reduction in size and increased angulation will allow bronchoscopists to use this device to biopsy more peripheral lung lesions [68] . 
